rss
Br J Ophthalmol 2009;93:1359-1364 doi:10.1136/bjo.2008.148155
  • Original Article
  • Clinical science

Frequency of ABCA4 mutations in 278 Spanish controls: an insight into the prevalence of autosomal recessive Stargardt disease

This article has been UnlockedFree via Creative Commons: OPEN ACCESS
  1. R Riveiro-Alvarez1,2,
  2. J Aguirre-Lamban1,2,
  3. M Angel Lopez-Martinez1,2,
  4. M Jose Trujillo-Tiebas1,2,
  5. D Cantalapiedra1,2,
  6. E Vallespin1,2,
  7. A Avila-Fernandez1,2,
  8. C Ramos1,2,
  9. C Ayuso1,2
  1. 1
    Fundación Jimenez Diaz, Genetics Department, Madrid, Spain
  2. 2
    Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain
  1. Correspondence to Dr R Riveiro-Alvarez, Fundación Jimenez Diaz, Genetics Department, Avd. Reyes Catolicos 2, 28.040-Madrid, Spain; rriveiro{at}fjd.es
  • Accepted 20 October 2008
  • Published Online First 31 October 2008

Abstract

Aim: To determine the carrier frequency of ABCA4 mutations in order to achieve an insight into the prevalence of autosomal recessive Stargardt disease (arSTGD) in the Spanish population.

Methods: arSTGD patients (n = 133) were analysed using ABCR400 microarray and sequencing. Control subjects were analysed by two different strategies: 200 individuals were screened for the p.Arg1129Leu mutation by denaturing-HPLC and sequencing; 78 individuals were tested for variants with the microarray and sequencing.

Results: For the first strategy in control subjects, the p.Arg1129Leu variant was found in two heterozygous individuals, which would mean a carrier frequency for any variant of ~6.0% and a calculated arSTGD prevalence of 1:1000. For the second strategy, carrier frequency was 6.4% and therefore an estimated prevalence of the disease of 1:870.

Conclusion: Calculated prevalence of arSTGD based on the ABCA4 carrier frequency could be considerably higher than previous estimation. This discrepancy between observed (genotypic) and estimated (phenotypic) prevalence could be due to the existence of non-pathological or low penetrance alleles, which may result in late-onset arSTGD or may be implicated in age-related macular degeneration. This situation should be regarded with especial care when genetic counselling is given and further follow-up of these patients should be recommended.

Footnotes

  • Funding Supported by FIS (Health Research Fund) 06/0027, Fundacion Mutua Madrileña (30171/005) and EviGenoRet (LSHG-CT-2005-512036). R R-A’s work is supported by CIBER-ER from the Instituto de Salud Carlos III (06/07/0036).

  • Competing interests None declared.

  • Ethics approval This study was reviewed and approved by the Ethics Committee of the Hospital (Fundacion Jimenez Diaz) and it was performed according to the tenets of the Declaration of Helsinki and further reviews (Edinburgh, 2000; http://www.wma.net).

  • Patient consent Obtained.

This article has been Unlocked
Free via Creative Commons: OPEN ACCESS

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Free archive
The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.